A Digital Health App to Prevent Falls and Improve Well-being in People With Dementia
- Disease/Condition
- Dementia
- Drug/Device/Intervention
- Keep-on-Keep-Up
- Study type
- Interventional
- Intervention type
- other
- Primary sponsor
- Jaheeda Gangannagaripalli
- Funder
- University of Manchester
- Phase
- N/A
- Start date
- Nov 30, 2023
- End date
- Sep 01, 2024
- Enrollment
- 60 participants
The feasibility and acceptability of the intervention will be evaluated in terms of recruitment, retention and adherence rates to the trial.
Keep on Keep up (KOKU) is a tablet/iPad-based, digital strength and balance exercise
 programme specifically designed for older people at risk of falls. Research has shown that
 the exercises reduce falls by around a third in older people. People with Dementia are more
 reluctant and have greater challenges with using digital technologies. Evidence suggests that
 developing technologies in a Patient-Centered manner will be more acceptable in this
 population as People with Dementia are more reluctant to using digital technologies. The
 existing version of the KOKU app has been modified in collaboration with People with Dementia
 and carers to suit their needs and make it Dementia-friendly and accessible to people with
 Dementia. The current project involves testing the modified new version of the KOKU app with
 people with Dementia, their carers, and health and social care professionals. This project
 will have many possible benefits for people with Dementia; It has the potential to improve
 quality of life (QoL), well-being, confidence, independence, and therefore has the potential
 to reduce general practice visits, hospital admissions, and health and social care costs.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06149702
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06149702 through Pure Global AI's free database. This phase not specified trial is sponsored by Jaheeda Gangannagaripalli and is currently Not yet recruiting. The study focuses on Dementia. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.